SCHEMBL15720555

SCHEMBL15720555

CC(C)(N)Cc1c(-c2cccc(Br)c2)nc2ccc(C(F)(F)F)cn12

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 8/20 0.64
▸ PSMD14 O00487 2/20 0.45
▸ SLC2A1 P11166 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ PRNP P04156 2/20 0.38
▸ MEN1 O00255 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ NR1H4 Q96RI1 1/20 0.36
▸ USP7 Q93009 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15720556 0.78 TRPA1 (1.00) TRPA1MEN1KMT2A
SCHEMBL1691718 0.73 SLC2A1 (0.49) TRPA1SLC2A1TDP1NR1H4
SCHEMBL1691844 0.72 SLC2A1 (0.51) TRPA1SLC2A1KDM4EPRNPMEN1
SCHEMBL15720380 0.72 TRPA1 (0.62) TRPA1PSMD14SLC2A1KDM4EHSD17B10
SCHEMBL15720498 0.70 TRPA1 (0.64) TRPA1PSMD14SLC2A1PRNPNR1H4
SCHEMBL1691706 0.68 SLC2A1 (0.51) TRPA1SLC2A1KDM4EHSD17B10POLB
SCHEMBL3021592 0.67 ALDH1A1 (0.70) TRPA1PSMD14SLC2A1KDM4EPRNP
SCHEMBL15720413 0.67 TRPA1 (0.66) TRPA1PSMD14PRNPKMT2ANR1H4
SCHEMBL15720398 0.66 TRPA1 (0.64) TRPA1PSMD14SLC2A1PRNP
SCHEMBL15740030 0.66 TRPA1 (1.00) TRPA1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394304-B2 Imidazopyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2016-07-19 — — US claimed
EP-2920169-A1 IMIDAZOPYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2015-09-23 — — EP claimed
US-20150246918-A1 IMIDAZOPYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-09-03 — — US claimed
WO-2014076021-A1 IMIDAZOPYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2014-05-22 — — WO claimed
US-9394304-B2 Imidazopyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2016-07-19 — — US disclosed
EP-2920169-A1 IMIDAZOPYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2015-09-23 — — EP disclosed
US-20150246918-A1 IMIDAZOPYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-09-03 — — US disclosed
WO-2014076021-A1 IMIDAZOPYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2014-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246918-A1 IMIDAZOPYRIDINE DERIVATIVES QDPR, ADRB3, HRH4 TRPA1 882/4885PSMD14 2224/4885SLC2A1 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback